{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:42:36Z","timestamp":1787020956285,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100008990","name":"Science and Technology Department of Zhejiang Province","doi-asserted-by":"crossref","award":["2023C03163"],"award-info":[{"award-number":["2023C03163"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02837-4","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T04:30:50Z","timestamp":1753849850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Longitudinal serum total bile acid trajectories and risk of metabolic dysfunction-associated fatty liver disease: a retrospective cohort study"],"prefix":"10.1186","volume":"30","author":[{"given":"Huihui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueni","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingni","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenya","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"issue":"3","key":"2837_CR1","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1016\/j.cgh.2021.01.030","volume":"20","author":"RJ Wong","year":"2022","unstructured":"Wong RJ, Cheung R. Trends in the prevalence of metabolic dysfunction-associated fatty liver disease in the United States, 2011\u20132018. Clin Gastroenterol Hepatol. 2022;20(3):e610\u20133.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2837_CR2","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1210\/clinem\/dgab644","volume":"107","author":"X Wang","year":"2022","unstructured":"Wang X, Wu S, Yuan X, Chen S, Fu Q, Sun Y, et al. Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study. J Clin Endocrinol. 2022;107(2):e745\u201355.","journal-title":"J Clin Endocrinol"},{"issue":"1","key":"2837_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384.","journal-title":"Hepatology"},{"issue":"11","key":"2837_CR4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/hepr.13685","volume":"51","author":"T Tsutsumi","year":"2021","unstructured":"Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115\u201328.","journal-title":"Hepatol Res"},{"issue":"10","key":"2837_CR5","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1007\/s10620-022-07508-6","volume":"67","author":"H Kim","year":"2022","unstructured":"Kim H, Lee CJ, Ahn SH, Lee KS, Lee BK, Baik SJ, et al. MAFLD predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check-ups. Dig Dis Sci. 2022;67(10):4919\u201328.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"2837_CR6","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","volume":"75","author":"D Kim","year":"2021","unstructured":"Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75(6):1284\u201391.","journal-title":"J Hepatol"},{"issue":"1","key":"2837_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"issue":"2","key":"2837_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3727\/105221618X15156018385515","volume":"18","author":"JYL Chiang","year":"2018","unstructured":"Chiang JYL, Ferrell JM. Bile acid metabolism in liver pathobiology. Gene Expr. 2018;18(2):71\u201387.","journal-title":"Gene Expr"},{"key":"2837_CR9","doi-asserted-by":"publisher","first-page":"111618","DOI":"10.1016\/j.mce.2022.111618","volume":"548","author":"JYL Chiang","year":"2022","unstructured":"Chiang JYL, Ferrell JM. Discovery of farnesoid X receptor and its role in bile acid metabolism. Mol Cell Endocrinol. 2022;548:111618.","journal-title":"Mol Cell Endocrinol"},{"key":"2837_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mam.2017.04.004","volume":"56","author":"MD Chow","year":"2017","unstructured":"Chow MD, Lee YH, Guo GL. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med. 2017;56:34\u201344.","journal-title":"Mol Aspects Med"},{"issue":"1","key":"2837_CR11","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/j.2040-4603.2022.tb00205.x","volume":"12","author":"PB Hylemon","year":"2021","unstructured":"Hylemon PB, Su L, Zheng PC, Bajaj JS, Zhou H. Bile acids, gut microbiome and the road to fatty liver disease. Compr Physiol. 2021;12(1):2719\u201330.","journal-title":"Compr Physiol"},{"issue":"7","key":"2837_CR12","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","volume":"158","author":"BA Neuschwander-Tetri","year":"2020","unstructured":"Neuschwander-Tetri BA. Therapeutic landscape for NAFLD in 2020. Gastroenterology. 2020;158(7):1984\u201398.","journal-title":"Gastroenterology"},{"issue":"5","key":"2837_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/apt.14492","volume":"47","author":"B Hameed","year":"2018","unstructured":"Hameed B, Terrault NA, Gill RM, Loomba R, Chalasani N, Hoofnagle JH, et al. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2018;47(5):645\u201356.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2837_CR14","doi-asserted-by":"publisher","first-page":"100222","DOI":"10.1016\/j.jhepr.2020.100222","volume":"3","author":"G Grzych","year":"2020","unstructured":"Grzych G, Ch\u00e1vez-Talavera O, Descat A, Thuillier D, Verrijken A, Kouach M, et al. NASH-related increases in plasma bile acid levels depend on insulin resistance. JHEP Rep. 2020;3(2):100222.","journal-title":"JHEP Rep"},{"issue":"8","key":"2837_CR15","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/1753-0407.13040","volume":"12","author":"W Zhu","year":"2020","unstructured":"Zhu W, Wang S, Dai H, Xuan L, Deng C, Wang T, et al. Serum total bile acids associate with risk of incident type 2 diabetes and longitudinal changes in glucose-related metabolic traits. J Diabetes. 2020;12(8):616\u201325.","journal-title":"J Diabetes"},{"issue":"7","key":"2837_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JR, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and fl-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412\u20139.","journal-title":"Diabetologia"},{"issue":"2","key":"2837_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","volume":"68","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68(2):305\u201315.","journal-title":"J Hepatol"},{"issue":"5","key":"2837_CR18","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264\u201381.","journal-title":"Gastroenterology"},{"issue":"4","key":"2837_CR19","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846\u201354.","journal-title":"Hepatology"},{"issue":"6","key":"2837_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325.","journal-title":"Hepatology"},{"issue":"10","key":"2837_CR21","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1007\/s10620-017-4721-9","volume":"62","author":"JS Redman","year":"2017","unstructured":"Redman JS, Natarajan Y, Hou JK, Wang J, Hanif M, Feng H, et al. Accurate identification of fatty liver disease in data warehouse utilizing natural language processing. Dig Dis Sci. 2017;62(10):2713\u20138.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"2837_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1037\/1082-989X.6.1.18","volume":"6","author":"DS Nagin","year":"2001","unstructured":"Nagin DS. Analyzing developmental trajectories of distinct but related behaviors: a group-based method. Psychol Methods. 2001;6(1):18\u201334.","journal-title":"Psychol Methods"},{"issue":"2\u20133","key":"2837_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000360229","volume":"65","author":"DS Nagin","year":"2014","unstructured":"Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr Metab. 2014;65(2\u20133):205\u201310.","journal-title":"Ann Nutr Metab"},{"issue":"1","key":"2837_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12944-020-1201-6","volume":"19","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Dai W, Weng S, Luo M, Fu J, Zadroga JA, et al. The association of serum total bile acid with non-alcoholic fatty liver disease in Chinese adults: a cross sectional study. Lipids Health Dis. 2020;19(1):18.","journal-title":"Lipids Health Dis"},{"issue":"4","key":"2837_CR25","doi-asserted-by":"publisher","first-page":"304","DOI":"10.4103\/sjg.sjg_512_21","volume":"28","author":"Y Chen","year":"2022","unstructured":"Chen Y, Su H, Xue H, Wang T, Qian T, Liao C, et al. Correlation between serum total bile acid and nonalcoholic fatty liver disease: a cross-sectional study. Saudi J Gastroenterol. 2022;28(4):304.","journal-title":"Saudi J Gastroenterol"},{"key":"2837_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.freeradbiomed.2019.05.029","volume":"144","author":"G Svegliati-Baroni","year":"2019","unstructured":"Svegliati-Baroni G, Pierantonelli I, Torquato P, Marinelli R, Ferreri C, Chatgilialoglu C, et al. Lipidomic biomarkers and mechanisms of lipotoxicity in non-alcoholic fatty liver disease. Free Radic Biol Med. 2019;144:293\u2013309.","journal-title":"Free Radic Biol Med"},{"issue":"12","key":"2837_CR27","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1111\/liv.15030","volume":"41","author":"Y Jung","year":"2021","unstructured":"Jung Y, Koo BK, Jang SY, Kim D, Lee H, Lee DH, et al. Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus. Liver Int. 2021;41(12):2892\u2013902.","journal-title":"Liver Int"},{"issue":"2","key":"2837_CR28","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/hep.29359","volume":"67","author":"P Puri","year":"2018","unstructured":"Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S, et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatol Baltim Md. 2018;67(2):534\u201348.","journal-title":"Hepatol Baltim Md"},{"issue":"4","key":"2837_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/hep4.1490","volume":"4","author":"SY Kwan","year":"2020","unstructured":"Kwan SY, Jiao J, Qi J, Wang Y, Wei P, McCormick JB, et al. Bile acid changes associated with liver fibrosis and steatosis in the Mexican-American population of South Texas. Hepatol Commun. 2020;4(4):555\u201368.","journal-title":"Hepatol Commun"},{"issue":"3","key":"2837_CR30","doi-asserted-by":"publisher","first-page":"154457","DOI":"10.1016\/j.metabol.2020.154457","volume":"116","author":"N Nimer","year":"2021","unstructured":"Nimer N, Choucair I, Wang Z, Nemet I, Li L, Gukasyan J, et al. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression. Metabolism. 2021;116(3):154457.","journal-title":"Metabolism"},{"issue":"4","key":"2837_CR31","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/hep.30908","volume":"71","author":"F Chen","year":"2020","unstructured":"Chen F, Esmaili S, Rogers GB, Bugianesi E, Petta S, Marchesini G, et al. Lean NAFLD: a distinct entity shaped by differential metabolic adaptation. Hepatology. 2020;71(4):1213\u201327.","journal-title":"Hepatology"},{"issue":"4","key":"2837_CR32","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/hep.26225","volume":"57","author":"LP Bechmann","year":"2013","unstructured":"Bechmann LP, Kocabayoglu P, Sowa JP, Sydor S, Best J, Schlattjan M, et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology. 2013;57(4):1394\u2013406.","journal-title":"Hepatology"},{"issue":"7075","key":"2837_CR33","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature04330","volume":"439","author":"M Watanabe","year":"2006","unstructured":"Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439(7075):484\u20139.","journal-title":"Nature"},{"issue":"4","key":"2837_CR34","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/pr.113.008201","volume":"66","author":"T Li","year":"2014","unstructured":"Li T, Chiang JYL. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014;66(4):948\u201383.","journal-title":"Pharmacol Rev"},{"issue":"11","key":"2837_CR35","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.cell.2024.03.034","volume":"187","author":"Q Nie","year":"2024","unstructured":"Nie Q, Luo X, Wang K, Ding Y, Jia S, Zhao Q, et al. Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway. Cell. 2024;187(11):2717-2734.e33.","journal-title":"Cell"},{"issue":"8","key":"2837_CR36","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.3390\/nu13082649","volume":"13","author":"M Cerreto","year":"2021","unstructured":"Cerreto M, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Bariatric surgery and liver disease: general considerations and role of the gut-liver axis. Nutrients. 2021;13(8):2649.","journal-title":"Nutrients"},{"issue":"10","key":"2837_CR37","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1111\/1751-7915.14293","volume":"16","author":"W Wu","year":"2023","unstructured":"Wu W, Kaicen W, Bian X, Yang L, Ding S, Li Y, et al. Akkermansia muciniphila alleviates high-fat-diet-related metabolic-associated fatty liver disease by modulating gut microbiota and bile acids. Microb Biotechnol. 2023;16(10):1924\u201339.","journal-title":"Microb Biotechnol"},{"issue":"10","key":"2837_CR38","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41575-022-00635-5","volume":"19","author":"M Eslam","year":"2022","unstructured":"Eslam M, El-Serag HB, Francque S, Sarin SK, Wei L, Bugianesi E, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638\u201351.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2837_CR39","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1038\/ncomms5309","volume":"5","author":"YL Liu","year":"2014","unstructured":"Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JBS, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:4309.","journal-title":"Nat Commun"},{"issue":"4","key":"2837_CR40","doi-asserted-by":"publisher","first-page":"bqaa017","DOI":"10.1210\/endocr\/bqaa017","volume":"161","author":"P Sangwung","year":"2020","unstructured":"Sangwung P, Petersen KF, Shulman GI, Knowles JW. Mitochondrial dysfunction, insulin resistance, and potential genetic implications. Endocrinology. 2020;161(4):bqaa017.","journal-title":"Endocrinology"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02837-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02837-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02837-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T07:22:50Z","timestamp":1757316170000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02837-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2837"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02837-4","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Institutional Research Ethics Committee of the Second Affiliated Hospital, School of Medicine, Zhejiang University (No.2024-1517). The ethics committee waived the requirement of written informed consent for participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final version of the manuscript and agree to its submission to Scientific Reports. We confirm that this work is original and has not been published elsewhere, nor is it currently under consideration for publication elsewhere.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"685"}}